We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$414M
AUM Growth
-$24.8M
(-5.7%)
Cap. Flow
+$88.7M
Cap. Flow
% of AUM
21.41%
Top 10 Holdings %
Top 10 Hldgs %
52.02%
Holding
86
New
35
Increased
13
Reduced
20
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$19.1M |
| 2 |
Sanofi
SNY
|
+$18.3M |
| 3 |
Labcorp
LH
|
+$13.4M |
| 4 |
Cencora
COR
|
+$11.5M |
| 5 |
Charles River Laboratories
CRL
|
+$7.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$19.5M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.5M |
| 3 |
Icon
ICLR
|
+$12.2M |
| 4 |
Johnson & Johnson
JNJ
|
+$9.06M |
| 5 |
ACH
Accendra Health
ACH
|
+$7.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.05% |
| 2 | Industrials | 1.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nurix Therapeutics
NRIX
$2.62B
| $1.26M | 0.3% |
+43,542
| New | +$1.32M |
|
|
GBT
52
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.25M | 0.3% |
+42,797
| New | +$1.33M |
|
53
DarioHealth
DRIO
$75.6M
| $1.18M | 0.28% |
4,549
-2,951
| -39% | -$898K |
|
54
Accuray
ARAY
$33.8M
| $1.17M | 0.28% |
+245,764
| New | +$1.18M |
|
55
Treace Medical Concepts
TMCI
$284M
| $1.07M | 0.26% |
+57,175
| New | +$1.18M |
|
|
MTEM
56
DELISTED
Molecular Templates, Inc.
MTEM
| $1.05M | 0.25% |
17,892
-23,017
| -56% | -$1.72M |
|
57
Iovance Biotherapeutics
IOVA
$2.77B
| $1.03M | 0.25% |
53,981
-77,117
| -59% | -$1.7M |
|
|
ACH
58
Accendra Health
ACH
$224M
| $978K | 0.24% |
22,489
-181,295
| -89% | -$7.11M |
|
|
PHAS
59
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $940K | 0.23% |
360,078
-772,445
| -68% | -$2.33M |
|
|
BHVN
60
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $836K | 0.2% |
+6,069
| New | +$772K |
|
61
Community Health Systems
CYH
$416M
| $597K | 0.14% |
+44,847
| New | +$563K |
|
62
Orthofix Medical
OFIX
$428M
| $585K | 0.14% |
+18,817
| New | +$629K |
|
|
HGEN
63
DELISTED
HUMANIGEN, INC.
HGEN
| $575K | 0.14% |
+154,613
| New | +$905K |
|
64
ARS Pharmaceuticals
SPRY
$551M
| $561K | 0.14% |
+84,295
| New | +$685K |
|
65
AngioDynamics
ANGO
$625M
| $500K | 0.12% |
+18,125
| New | +$500K |
|
|
66
AbbVie
ABBV
$431B
| – | – |
-180,429
| Closed | -$19.5M |
|
67
Aclaris Therapeutics
ACRS
$851M
| – | – |
-67,300
| Closed | -$1.21M |
|
68
Actinium Pharmaceuticals
ATNM
$24.7M
| $0 | ﹤0.01% |
+66,666
| New | +$500K |
|
69
AptarGroup
ATR
$8.63B
| – | – |
-51,191
| Closed | -$6.11M |
|
|
70
Bristol-Myers Squibb
BMY
$131B
| – | – |
-211,821
| Closed | -$12.5M |
|
71
Bolt Biotherapeutics
BOLT
$7.44M
| – | – |
-4,502
| Closed | -$1.14M |
|
|
72
Icon
ICLR
$12.4B
| – | – |
-46,720
| Closed | -$12.2M |
|
73
Krystal Biotech
KRYS
$9.55B
| – | – |
-22,938
| Closed | -$1.2M |
|
74
McKesson
MCK
$102B
| – | – |
-32,551
| Closed | -$6.49M |
|
|
MREO
75
Mereo BioPharma
MREO
$48.8M
| – | – |
-746,514
| Closed | -$1.81M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Endurant Capital Management held 86 positions worth $414M, down 5.7% from $439M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Endurant Capital Management deployed $88.7M of net new capital in Q4 2021, opening 35 new positions and adding to 13 existing holdings. Its largest new stake was AstraZeneca: 162,364 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 60% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $9.06M trimmed.
- Endurant Capital Management's largest Q4 2021 buy was AstraZeneca: 162,364 shares worth $18.9M.
- Endurant Capital Management added most to Sanofi in Q4 2021, an estimated $18.3M increase.
- Endurant Capital Management's biggest Q4 2021 reduction was Johnson & Johnson, cutting an estimated $9.06M.
- Endurant Capital Management fully exited AbbVie in Q4 2021, selling an estimated $19.5M.
- Endurant Capital Management's ten largest holdings make up 52% of its $414M portfolio in Q4 2021.
- Endurant Capital Management opened 35 new positions and closed 18 in Q4 2021.
- Endurant Capital Management's portfolio value fell 5.7% quarter-over-quarter to $414M.
Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.